BPC-157
A 15-amino-acid peptide derived from human gastric juice with remarkable tissue-healing properties across tendons, ligaments, muscle, gut, and brain.
Also known as: Body Protection Compound-157, Bepecin, PL 14736, PL-10
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
BPC-157 is a stable gastric pentadecapeptide that promotes angiogenesis through upregulation of VEGF and the FAK-paxillin pathway, accelerating blood vessel formation at injury sites. It modulates the nitric oxide system, exerts cytoprotective effects on the GI mucosa, and has demonstrated healing of tendons, ligaments, muscles, nerves, and bones in numerous animal models. It also appears to influence the dopaminergic and serotonergic systems, providing neuroprotective and anxiolytic effects.
Common Applications
Safety & Considerations
Preclinical safety data is extensive with no reported toxicity in animal studies at any tested dose. Human clinical data is limited to oral formulations for IBD (Phase II). Common self-reported side effects in anecdotal use include nausea and dizziness. Long-term human safety has not been established. Currently not legal for compounding in the US under FDA Category 2 designation.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.